Rational Pharmacotherapy Selection for Insomnia

Slides:

Advertisements

Similar presentations

LESSON 1.4: DEPRESSION Unit 1: Mental Health. Do Now  Fill in the K-W-L chart with what you know and want to know about depression. KNOWWANT TO KNOW.

Advertisements

Meredith Cook Mercer COPHS August, Beers Criteria AGS and interdisciplinary panel of 11 experts in geriatrics and pharmacotherapy 53 medications.

Primary Insomnia Edwin Alvarado Period 5. Definition  Chronic inability to fall asleep or remain asleep for an adequate amount of time.

Insomnia Insomnia is a sleep disorder that is defined by difficulty falling asleep. There are two types of insomnia: – Primary insomnia: the insomnia.

Mood Disorders: Depression Chapter 12. Defined as a depressed mood or loss of interest that lasts at least 2 weeks & is accompanied by symptoms such as.

 Sleep: Treatment and Cause for Low Back Pain Kevin Carneiro, D.O. University of North Carolina, Chapel Hill.

Suvorexant for Insomnia

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Multimodal Management of Opioid-Induced Constipation

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Psoriatic Arthritis.

Primary Care Challenges in Depression - To Treat or Refer?

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Starting Strong: Initial Evaluation of the Patient With HCV

The Clinical Enigma of Cardiogenic Shock

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Emerging Data on ACS Management From ACC

The Nurse View.

The Patient Journey to Remission in MDD: A Collaborative Approach

COPD Management.

Managing Complex Hypertension: What Every Physician Should Know

Improving Acne Outcomes

Neurostimulation for the Management of Medication-Resistant Epilepsy

Case Challenges in Chronic Migraine

Beyond the Basics: What You Need to Know About Treating Insomnia

Successful Obesity Management and Counseling:

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Managing Depression in Bipolar I Disorder

Treating HFrEF: Challenges Faced

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

HCV Protease Inhibitors in Clinical Practice

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Improving Outcomes in OSA

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Managing Depression is a Team Effort:

Updates in Neurogenic Orthostatic Hypotension

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

Treating to Target in MS

Hidden in Plain Sight: Disrupted Sleep in Patients With Pain

Multidisciplinary Management of Hyperkalemia:

Traditional Stimulants vs Other Wake-Promoting Agents

Clinicians' Corner in Dyslipidemia

The Road to Quality Improvement in HER2-Positive Breast Cancer

When Is Intrathecal Drug Delivery Appropriate?

New Approaches to Insomnia Management: Impact on Clinical Practice

HCV Protease Inhibitors in Clinical Practice

Considerations for Managing Insomnia in Older Adults

Critical Decision Points in Insomnia

Update on OTC Pain Relievers for Osteoarthritis

Extraordinary Cases in VTE

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Current Controversies and Advances in Hepatorenal Syndrome

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Assessing the Burden of Hyperkalemia

Selecting Treatment Approaches in Hemophilia

When Is Intrathecal Drug Delivery Appropriate?

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Assessing the Burden of Hyperkalemia

Understanding the Nature of Sleep and How it Changes With Age

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Merging the Art and Science of Managing nOH in Clinical Practice

Diagnostic Criteria Migraine Without Aura

Anemia Explored.

PCSK9 Inhibitors and Real-World Evidence

Navigating the Journey

Understanding the Basics of Dementia-Related Psychosis

Multimodal Approaches to Cracking the Code in Low Back Pain

Presentation transcript:

Rational Pharmacotherapy Selection for Insomnia

Insomnia Prevalence

Triad of Insomnia Symptoms

Insomnia Subtypes

Insomnia-Associated Conditions and Outcomes

Falls in Older Adults

Bidirectional Relationship Between Sleep and Health

CSF-Orexin Concentrations in Patients With and Without MCI and Sleep Complaints

The Rational Treatment of Insomnia Is Based on the Neurobiology of Sleep

Arousal Systems in People With Insomnia That Do not Deactivate From Waking to Sleep

Wake-Promoting vs Sleep-Inducing Brain Centers and Neurotransmitters

Hyperarousal Model of Insomnia

Arousal Systems in People With Insomnia That Do not Deactivate From Waking to Sleep

Goals of Treatment in Insomnia

Personalized Treatment Selection

CBT-I First-Line Therapy

Site of Action of Drugs to Treat Insomnia

Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

FDA-Approved Insomnia Medications

Half-Life of FDA-Approved Drugs for the Treatment of Insomnia

Drugs in the Pipeline for Insomnia

AASM Chronic Insomnia Clinical Guideline Consensus Recommendations

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)